Morgan Stanley Imv Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	BUY	$0.56 - $1.45 $933 - $2,417	1,667 Added 4.81%	36,314 $23,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.45 $933 - $2,417	1,667 Added 4.81%	36,314 $23,000
Q1 2022 Oct 27, 2022	SELL	$1.07 - $1.5 $1,783 - $2,500	-1,667 Reduced 4.59%	34,647 $48,000
Q1 2022 May 13, 2022	SELL	$1.07 - $1.5 $16,445 - $23,055	-15,370 Reduced 30.73%	34,647 $48,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.78 $13,221 - $19,289	10,837 Added 27.66%	50,017 $61,000
Q3 2021 Nov 15, 2021	BUY	$1.35 - $2.16 $52,893 - $84,628	39,180 New	39,180 $65,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.